TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2295294

Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK antagonist), 800 mg (two tablets of 400 mg each)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 381006

Group type: EXPERIMENTAL
Intervention: (‐)eburnamonine (80 mg/day for the first 5 days, then 60 mg/day for at least 20 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nicergoline (20 mg/day for the first 5 days, then 15 mg/day for at least 20 days)
Number of subjects: 28
Study: 7013976

Group type: EXPERIMENTAL
Intervention: Doxorubicin (300 mg/kg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cycloleucine (300 mg/kg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cycloleucine (200 mg/kg)
Number of subjects: 51
Study: 30834253

Group type: EXPERIMENTAL
Intervention: Galphimine-B standardized extract
Number of subjects: 167

Group type: COMPARATOR
Intervention: Alprazolam (control)
Number of subjects: 167
Study: 28762160

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for children with ASD
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waitlisted parents (Control)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All parents (including treatment and control)
Number of subjects: 57
Study: 26106962

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination formulation
Number of subjects: 161

Group type: COMPARATOR
Intervention: Separate formulations
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 161
Study: 24400967

Group type: EXPERIMENTAL
Intervention: Breastfeeding self-efficacy intervention (three individualized sessions)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard care (referent group)
Number of subjects: 74
Study: 22695489

Group type: EXPERIMENTAL
Intervention: Almorexant 400 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Almorexant 1000 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Almorexant (evening administration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19947279

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 978

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 978
Study: 17526469

Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/d) with diet modifications (500 kcal/d less than usual) and moderate physical activity (jogging lightly for 30 min 3 times a week)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg/d) only
Number of subjects: 28
Study: 15583924

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with HELBO Blue and TheraLite laser
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group without aPDT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Number of subjects: 100
Study: 12297170

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU loading dose and 0.5 x 10(6) KIU/h during surgery, n=22)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Saline solution (control, n=25)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Aprotinin (n=22)
Number of subjects: 47
Study: 10429750

Group type: EXPERIMENTAL
Intervention: Intervention group (received the intervention in spring 1994)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Wait-list control group (received the intervention in spring 1995)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intervention group (parents of children attending centers in the intervention group)
Number of subjects: 27
Study: 7770327

Group type: EXPERIMENTAL
Intervention: Resource allocation manipulation through dual task priority
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporal predictability manipulation of discrete stimuli
Number of subjects: 0
Study: 2179711

Group type: EXPERIMENTAL
Intervention: Gen-Probe (chemiluminescent technique of nucleic acid hybridization)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Chlamydiazyme (Abbott Labs)
Number of subjects: 187

Group type: COMPARATOR
Intervention: MicroTrak (Syva)
Number of subjects: 187
Study: 383287

Group type: EXPERIMENTAL
Intervention: High-dose methanol extraction residue fraction of Bacillus Calmette-Guérin (MER) (2.0 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low-dose methanol extraction residue fraction of Bacillus Calmette-Guérin (MER) (0.5 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 0.9% NaCl solution placebo
Number of subjects: 84
Study: 31304775

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) at 2 mA for 20 minutes per session, with 30 seconds ramp-up and ramp-down.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation (30 seconds ramp-up to 2 mA, 10 seconds stimulation, 30 seconds ramp-down, and 20 minutes no current).
Number of subjects: 30
Study: 28526870

Group type: EXPERIMENTAL
Intervention: Muscular strength endurance (SE)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Muscular hypertrophy (MH)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Maximum strength (MS)
Number of subjects: 45
Study: 26200180

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic normoglycemic clamp (HNC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy (insulin treatment if glucose >150 mg/dl)
Number of subjects: 100
Study: 23455443

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Enteral Nutrition (EN+PN)
Number of subjects: 353
Study: 21801540

Group type: EXPERIMENTAL
Intervention: Neostatin (lipid-lowering drug)
Number of subjects: 900
Study: 19855033

Group type: EXPERIMENTAL
Intervention: Higher BMI, higher age, and higher numbers of current somatic and mental disorders
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Higher numbers of both mental and somatic disorders, female gender, and younger age
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Therapy status
Number of subjects: 640
Study: 17112001

Group type: EXPERIMENTAL
Intervention: Topotecan plus cisplatin (TC)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Cisplatin monotherapy
Number of subjects: 293
Study: 15293627

Group type: EXPERIMENTAL
Intervention: Prognostic factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox model
Number of subjects: 0
Study: 12110777

Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 50
Study: 9449397

Group type: EXPERIMENTAL
Intervention: Ang I infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ang II infusion
Number of subjects: 17
Study: 7831698

Group type: EXPERIMENTAL
Intervention: Dextrorphan (loading dose 60 to 150 mg, maintenance infusion maximum total dose 3310 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dextrorphan (loading dose 145 to 260 mg, maintenance infusion 30 to 70 mg/h)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 2194442

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids (high dose, short term)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study: 508554

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30010027

Group type: EXPERIMENTAL
Intervention: HEART Camp intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 204
Study: 26655433

Group type: EXPERIMENTAL
Intervention: 4-week home-based telerehabilitation exercise program using virtual reality (VR) in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-week written home exercise program (usual care discharge home program)
Number of subjects: 0
Study: 25072647

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide 2% and timolol 0.5% twice daily postoperatively until gas dissolution
Number of subjects: 21

Group type: COMPARATOR
Intervention: Observation (Control group)
Number of subjects: 21
Study: 22947356

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg to 20 mg daily
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg to 40 mg daily
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg to 20 mg + Lisinopril 10 mg to 40 mg
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 20453055

Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 1474

Group type: EXPERIMENTAL
Intervention: Behavioral skills
Number of subjects: 1474

Group type: EXPERIMENTAL
Intervention: Information
Number of subjects: 1474
Study: 17565094

Group type: EXPERIMENTAL
Intervention: Expressive-writing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: History-writing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Time-management
Number of subjects: 40
Study: 16130176

Group type: EXPERIMENTAL
Intervention: 40 mg of nemifitide administered by standard needle/syringe
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg of nemifitide administered by needle-free injection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 80 mg of nemifitide administered by needle-free injection
Number of subjects: 12
Study: 12135935

Group type: EXPERIMENTAL
Intervention: Pravastatin or Cerivastatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy subjects (Control)
Number of subjects: 80
Study: 10680452

Group type: EXPERIMENTAL
Intervention: Glutamine supplemented TPN for 10 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional TPN for 8-63 days
Number of subjects: 11
Study: 7566519

Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study: 1837469

Group type: EXPERIMENTAL
Intervention: 25-gauge Whitacre needle
Number of subjects: 200

Group type: COMPARATOR
Intervention: 22-gauge Whitacre needle
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (22-gauge and 25-gauge)
Number of subjects: 200
Study: 7072313

Group type: EXPERIMENTAL
Intervention: acebutolol (400 mg/die)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: diuretic mefrusid (25 mg/die)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: combination of acebutolol and mefrusid
Number of subjects: 42
Study: 31778707

Group type: COMPARATOR
Intervention: High altitude (HA)
Number of subjects: 8
Study: 30567753

Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 or 840 mg daily) combined with high-dose methotrexate (HD-MTX) at 3.5 g/m2 every 2 weeks for a total of 8 doses (4 cycles) and rituximab.
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-dose methotrexate (HD-MTX)
Number of subjects: 15
Study: 27155289

Group type: EXPERIMENTAL
Intervention: Labels containing 'tsp' or 'teaspoon' units (alone or with 'mL')
Number of subjects: 2110

Group type: COMPARATOR
Intervention: Labels containing 'mL' only
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Labels with 'teaspoon' spelled out
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Labels with 'teaspoon' and 'mL'
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Labels with 'tsp' and 'mL'
Number of subjects: 2110
Study: 25155032

Group type: EXPERIMENTAL
Intervention: Psychological prophylaxis training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 22747705

Group type: EXPERIMENTAL
Intervention: Motivational interviewing with computer assistance (MICA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Educational videos on contraception, STIs, and pre‐conception counseling
Number of subjects: 400
Study: 20950640

Group type: EXPERIMENTAL
Intervention: Standard leaflet plus brief, tailored feedback based on pre-screening questionnaire
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Standard leaflet on healthy lifestyle
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 365
Study: 17062840

Group type: EXPERIMENTAL
Intervention: LINS/SAL
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HINS/SAL
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: LINS/HI
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HINS/HI
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HI
Number of subjects: 9
Study: 16263089

Group type: EXPERIMENTAL
Intervention: Detection of delta-opioid receptors (DOR) and kappa-opioid receptors (KOR) in skin tissues
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry, Western blot, and immunofluorescence techniques
Number of subjects: 10
Study: 11867377

Group type: EXPERIMENTAL
Intervention: Physostigmine 2 mg IV
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 40
Study: 10714782

Group type: EXPERIMENTAL
Intervention: Initial Bohler's angle measurement
Number of subjects: 88
Study: 8846415

Group type: EXPERIMENTAL
Intervention: HOE‐140 (500 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HOE‐140 (5 min preadministration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HOE‐140 (2 h preadministration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HOE‐140
Number of subjects: 0
Study: 1533186

Group type: EXPERIMENTAL
Intervention: Desogestrel (150 micrograms/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (150 micrograms/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Monophasic ethinyloestradiol plus levonorgestrel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol plus desogestrel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Polyphasic ethinyloestradiol plus levonorgestrel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both progestins (desogestrel and levonorgestrel)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Addition of ethinyloestradiol to both progestins
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All combinations with ethinyloestradiol
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study: 3904820

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 51

Group type: COMPARATOR
Intervention: Adenine arabinoside
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Acyclovir (excluding prior antiviral treatment)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Adenine arabinoside (excluding prior antiviral treatment)
Number of subjects: 51
Study: 30466191

Group type: EXPERIMENTAL
Intervention: Mealtime fast-acting insulin aspart
Number of subjects: 606

Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 606
Study: 29127812

Group type: EXPERIMENTAL
Intervention: Baseline optimism
Number of subjects: 171
Study: 26484622

Group type: EXPERIMENTAL
Intervention: Turquoise LED light
Number of subjects: 91

Group type: COMPARATOR
Intervention: Blue LED light
Number of subjects: 91
Study: 26636096

Group type: EXPERIMENTAL
Intervention: Patient Activation Measure (PAM) score with one missing item
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Patient Activation Measure (PAM) score with twelve missing items
Number of subjects: 1138
Study: 24111974

Group type: EXPERIMENTAL
Intervention: Diazepam auto-injector (AI)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo auto-injector (AI)
Number of subjects: 234
Study: 20857087

Group type: EXPERIMENTAL
Intervention: Modified inside-out transobturator procedure
Number of subjects: 175

Group type: COMPARATOR
Intervention: Original inside-out transobturator procedure (TVT-O)
Number of subjects: 175
Study: 18326962

Group type: EXPERIMENTAL
Intervention: Mail education
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: In-class education
Number of subjects: 380
Study: 16793623

Group type: EXPERIMENTAL
Intervention: 4 mg estradiol benzoate injected intramuscularly
Number of subjects: 112

Group type: COMPARATOR
Intervention: Routine managements for uterine atony (control group)
Number of subjects: 112
Study: 12657225

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) administered for 3 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11080706

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 microg administered twice daily
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 800 microg administered twice daily
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 9475305

Group type: EXPERIMENTAL
Intervention: Subcutaneous jet-injection of recombinant human growth hormone (rhGH)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional needle-injection of recombinant human growth hormone (rhGH)
Number of subjects: 18
Study: 7714412

Group type: EXPERIMENTAL
Intervention: Insulin eyedrops (50 microliters of sterile normal saline containing varying insulin concentrations)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (50 microliters of sterile normal saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin eyedrops (100 U/ml in saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin eyedrops
Number of subjects: 8
Study: 2455115

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg q.d. added to nifedipine 20 mg b.i.d.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo q.d. added to nifedipine 20 mg b.i.d.
Number of subjects: 14
Study: 27893474

Group type: EXPERIMENTAL
Intervention: Galileo (GAL) whole-body vibration with squat exercises (N = 15)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Power-plate (POW) whole-body vibration with squat exercises (N = 14)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Galileo (GAL) whole-body vibration
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Power-plate (POW) whole-body vibration
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Galileo (GAL) and Power-plate (POW) groups
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Twice weekly squat exercises with whole-body vibration
Number of subjects: 43
Study: 26994090

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam 1.5 g every 8 hours for 7 days
Number of subjects: 800

Group type: COMPARATOR
Intervention: Levofloxacin 750 mg once daily for 7 days
Number of subjects: 800
Study: 25450083

Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3 (9 × 10^11 bacteria) daily for 6 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 22956006

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg twice daily for 2 days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Dexamethasone and Placebo
Number of subjects: 94
Study: 20795923

Group type: EXPERIMENTAL
Intervention: Usual care plus inspiratory muscle training using a threshold device, with an initial load of 30% of their maximal inspiratory pressure, increased by 10% daily, administered for 5 min, twice a day, 7 days a week from the commencement of weaning until extubation.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Usual care plus inspiratory muscle training
Number of subjects: 41
Study: 18773749

Group type: EXPERIMENTAL
Intervention: Pharmacological treatments (3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors, fibric acid derivatives, insulin sensitizers, cannabinoid receptor type 1 blockers)
Number of subjects: 0
Study: 15657503

Group type: EXPERIMENTAL
Intervention: Prone SPECT imaging
Number of subjects: 15

Group type: COMPARATOR
Intervention: Supine SPECT imaging
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both prone and supine imaging
Number of subjects: 15
Study: 12233990

Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8008680

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg daily)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Propranolol and Acebutolol therapy
Number of subjects: 31
Study: 2514195

Group type: EXPERIMENTAL
Intervention: IVF attempts in patients with unexplained infertility (UI)
Number of subjects: 143
Study: 31586949

Group type: COMPARATOR
Intervention: One IVIg course
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Two IVIg courses (early)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Two IVIg courses (late)
Number of subjects: 237
Study: 31234948

Group type: EXPERIMENTAL
Intervention: Growing Together parenting education kit
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard care information resources
Number of subjects: 1000
Study: 28685311

Group type: EXPERIMENTAL
Intervention: Nasal packing
Number of subjects: 72

Group type: COMPARATOR
Intervention: Trans-septal suturing
Number of subjects: 72
Study: 26037324

Group type: EXPERIMENTAL
Intervention: Person-centred care approach (two-day initial training and ongoing support)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Optimised usual care (medication review by psychiatrist/geriatrician)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Person-centred care approach
Number of subjects: 36

Group type: COMPARATOR
Intervention: Optimised usual care
Number of subjects: 36
Study: 23814044

Group type: EXPERIMENTAL
Intervention: TCH (six cycles of docetaxel plus carboplatin combined with trastuzumab administered for 1 year)
Number of subjects: 3222

Group type: COMPARATOR
Intervention: AC→TH (adjuvant doxorubicin and cyclophosphamide followed by docetaxel plus trastuzumab administered for 1 year)
Number of subjects: 3222

Group type: COMPARATOR
Intervention: AC→T (four cycles of adjuvant doxorubicin and cyclophosphamide followed by four cycles of docetaxel)
Number of subjects: 3222

Group type: EXPERIMENTAL
Intervention: TCH
Number of subjects: 3222
Study: 21938372

Group type: EXPERIMENTAL
Intervention: Bryan cervical disc arthroplasty
Number of subjects: 181

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 181